Arcus Biosciences slides 20% on stock offering, kidney-cancer data

SA Spotlight uses AI to summarize content published on Seeking Alpha. All summaries are reviewed by human editors prior to publication.

Shares of Arcus Biosciences (RCUS), a late clinical-stage biopharmaceutical company, tumbled almost 20% on Wednesday, closing at $19.10 after falling $4.65 on the day. The decline came a day after the company presented new clinical data for its lead oncology candidate, casdatifan, across multiple kidney-cancer treatment lines.

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.